AstraZeneca has reached an agreement with the Trump administration to lower the costs of certain medications in exchange for a three-year suspension of tariffs imposed by President Donald Trump. The arrangement focuses on reducing drug prices for Americans who rely on Medicaid, the federal program designed for low-income individuals, and also includes price cuts for recently launched medications.
As part of the deal, AstraZeneca will enhance direct access to its medicines by selling them through its own website and the newly introduced TrumpRx platform. Additionally, the agreement stipulates that the company must repatriate some of its overseas profits to the United States if drug prices abroad rise as a consequence of the deal.
Trump’s administration has indicated a willingness to impose a 100% tariff on branded drugs imported into the U.S. from countries outside the European Union, which currently pays a 15% rate. This development aligns AstraZeneca’s actions with a similar agreement reached by Pfizer earlier, indicating a trend of pharmaceutical firms yielding to pressures from the administration in hopes of favorable treatment regarding tariffs.
In remarks made at the White House, AstraZeneca’s Chief Executive Pascal Soriot praised the collaboration as a significant victory for patients in the U.S., echoing sentiments of optimism shared by shareholders regarding the future trajectory of drug policies in the country. Although AstraZeneca’s stock did not fluctuate significantly following the announcement, it has experienced a 29% increase in value throughout the year, a rise attributed in part to the momentum generated by Pfizer’s recent agreement.
This agreement marks AstraZeneca as the first foreign pharmaceutical company to secure such terms with the Trump administration, positioning it ahead of competitors like Eli Lilly, which was anticipated to finalize a similar pact. Soriot has emphasized AstraZeneca’s commitment to the U.S. market, sharing plans for a direct listing on the New York Stock Exchange in addition to its existing presence in London.
The company was among 17 pharmaceutical entities that responded to Trump’s call for binding commitments to reduce drug prices within the U.S. The arrangement signals a potential shift in the landscape of pharmaceutical pricing and regulation, as deals like this could influence how companies navigate their pricing strategies moving forward.
